The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 5, 2013, Pages 944-950

  Hernández Alava, Mónica ^a   Wailoo, Allan ^a   Wolfe, Fred ^b   Michaud, Kaleb ^b,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Economic evaluation; EQ 5D; HAQ; Health outcomes; Mapping; Pain; Quality of life; Rheumatoid arthritis

Indexed keywords

ADULT; ARTHRALGIA; ARTICLE; DISEASE SEVERITY; EQ 5D QUESTIONNAIRE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; UNITED STATES; VISUAL ANALOG SCALE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; GREAT BRITAIN; HEALTH STATUS INDICATORS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN MEASUREMENT; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84876713065     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes400     Document Type: Article

References (17)

1. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
2. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
3. Torrance G, Feeny D, Furlong W et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996;34: 702-22.
4. Bansback NJ, Marra C, Tsuchiya A et al. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:963-71.
5. Marra CA, Marion SA, Guh DP et al. Not all 'quality adjusted life years' are equal. J Clin Epidemiol 2007;60: 616-24.
6. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from southern Sweden. Int J Technol Assess 2009;25:181-9.
7. Wailoo AJ, Bansback N, Brennan A et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost effectiveness analysis. Arthritis Rheum 2008;58:939-46.
8. Hurst NP, Kind P, Ruta D et al. Measuring health related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol. Br J Rheumatol 1997;36: 551-9.
9. Brazier J, Yang Y, Tsuchiya A et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010;11:215-25.
10. Wolfe F, Michaud K, Wallenstein G. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis. J Rheumatol 2010;37:1615.
11. Harrison M, Lunt M, Verstappen SMM et al. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health Qual Life Outcomes 2010;8:21.
12. Harrison MJ, Bansback N, Marra C et al. Valuing health for clinical and economic decisions: directions relevant for rheumatologists. J Rheumatol 2011;38: 1770-5.
13. Scott DL, Khoshaba B, Choy EH et al. Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQoL in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ. Ann Rheum Dis 2007;66:1534-7.
14. Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D health state utility values. Value Health 2012;15:550-61.
15. Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology 2011;50:16-24.
16. McLachlan GJ, Peel D. Finite mixture models. New York: Wiley, 2000.
17. Chen Y-F, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229. 950